Study to analyze brains of kids with rare disorder

School of Medicine researchers have received a five-year, $2.7 million grant to detect and analyze differences in the brains of children with a rare illness, Wolfram syndrome. The disorder includes a severe form of diabetes, hearing and vision loss and kidney problems. Patients also eventually lose muscle control and coordination from brain degeneration.

Conscience legislation ignores medical providers committed to giving patients all necessary care

Advances in medicine allow doctors to keep patients alive longer, tackle fertility problems and extend the viability of premature babies. They also lead to a growing number of moral questions for both the medical provider and patient. “Across the country, so-called conscience legislation allows doctors and nurses to refuse to provide abortions, contraception, sterilizations, and end-of-life care,” says Elizabeth Sepper, JD, health law expert and professor of law at Washington University in St. Louis. “But legislators have totally overlooked the consciences of providers who have made the conscientious judgment to deliver care and of the patients who seek these treatments.” Sepper says that conscience in the medical setting needs to be protected more consistently. “The one-sided protection of refusal cannot stand,” she says. “Just as we wouldn’t say that giving students vouchers only for Christian schools furthers religious freedom, we can’t say that current conscience legislation successfully lives up to its goal of protecting conscience.

Washington People: Suresh Vedantham

They said it couldn’t be done. Suresh Vedantham, MD, professor of radiology and surgery, was planning a nationwide trial comparing treatments for deep vein thromboses — dangerous blood clots in the legs’ major veins. Prior attempts had failed to meet recruitment goals, but Vedantham was eager to test a new approach. Four years later, recruitment for ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis), his NIH-sponsored trial, has crossed the halfway mark.
Older Stories